NasdaqCM - Nasdaq Real Time Price USD

Immunome, Inc. (IMNM)

15.31 +0.03 (+0.20%)
As of 11:05 AM EDT. Market Open.
Loading Chart for IMNM
DELL
  • Previous Close 15.28
  • Open 15.32
  • Bid 15.23 x 600
  • Ask 15.44 x 300
  • Day's Range 15.19 - 15.65
  • 52 Week Range 4.44 - 30.96
  • Volume 258,468
  • Avg. Volume 793,495
  • Market Cap (intraday) 913.918M
  • Beta (5Y Monthly) 1.66
  • PE Ratio (TTM) --
  • EPS (TTM) -5.38
  • Earnings Date May 3, 2024 - May 7, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 35.33

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

immunome.com

55

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IMNM

Performance Overview: IMNM

Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

IMNM
43.08%
S&P 500
6.05%

1-Year Return

IMNM
188.87%
S&P 500
22.38%

3-Year Return

IMNM
48.24%
S&P 500
22.33%

5-Year Return

IMNM
--
S&P 500
51.07%

Compare To: IMNM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IMNM

Valuation Measures

Annual
As of 4/22/2024
  • Market Cap

    912.13M

  • Enterprise Value

    771.63M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    21.63

  • Price/Book (mrq)

    7.61

  • Enterprise Value/Revenue

    55.05

  • Enterprise Value/EBITDA

    -27.56

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -20.81%

  • Return on Equity (ttm)

    -156.45%

  • Revenue (ttm)

    14.02M

  • Net Income Avi to Common (ttm)

    -106.81M

  • Diluted EPS (ttm)

    -5.38

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    142.15M

  • Total Debt/Equity (mrq)

    1.38%

  • Levered Free Cash Flow (ttm)

    2.36M

Research Analysis: IMNM

Analyst Price Targets

33.00
35.33 Average
15.31 Current
38.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: IMNM

Fair Value

15.31 Current
 

Dividend Score

0 Low
IMNM
Sector Avg.
100 High
 

Hiring Score

0 Low
IMNM
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
IMNM
Sector Avg.
100 High
 

Research Reports: IMNM

  • Daily – Vickers Top Insider Picks for 08/24/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 08/23/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 08/20/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 08/19/2021

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     

People Also Watch